KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc. (NASDAQ:TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that it has been selected for addition to the NASDAQ Biotechnology Index®. The selection will become effective upon market open on Monday, December 21, 2015.
